Hemab Therapeutics Holdings, Inc. Common Stock
- COAG
- NASDAQ
- Biotechnology
- Coagulation Disorder Drugs
- Rare Blood Diseases
$30.07
Today −7.53%Quote Oct 16, 2026, 08:00 PM UTC
−27.05%over the last month
Max drawdown −31.2%From 1-month high −27.0%3 months −39.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.40B
Quote Oct 16
Next earnings
Nov 10
Expected, not confirmed
Analyst target
$51.40
+70.9% from here
Floor
$29.35
2.4% below price
Where the price sits
3 analysts
Analyst range, low to high
$36.00$64.00
- Price $30.07
- Resistance $30.98
- Consensus $51.40
Analysts' average target sits about 71% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about COAGPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
59